Allergic Asthma, Asthma
Conditions
Keywords
Epigenetics, Airway wall remodeling
Brief summary
Allergic asthma is a complex and heterogeneous disease caused by excessive responses to inhaled allergens. Current medication, including corticosteroids and bronchodilators, does not act on the origin of inflammation but rather combats symptoms, leaving many patients uncontrolled. Airway epithelium is critical for the initiation and progression of asthma pathology. We will include a 52 subjects divided over two groups: ongoing asthma (26 patients) and non-asthmatic healthy controls (26 subjects) in a cross-sectional study. All subjects will be extensively clinically characterized including respiratory symptoms/questionnaires, in- and expiratory CT-scans, and parameters of large and small airway function and inflammation. In addition, blood and nasal epithelial brushes will be obtained to study the genetic and epigenetic mechanisms of asthma. Finally, bronchoscopy with bronchial biopsies and brushes will be performed under conscious sedation. Bronchial biopsies from both patient groups will be used for single cell transcriptional analysis.
Interventions
PROCEDUREBronchoscopy
Bronchoscopy for retrieval of airway cells
Sponsors
University Medical Center Groningen
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Inclusion criteria for all subjects: * Age between 18 and 45 years old. * Smoking history ≤2 packyears. Specific inclusion criteria for the two groups: * Group 1. Patients with ongoing asthma * Age of onset of asthmatic symptoms: 0 - 18 years. * Documented history of asthma diagnosed according to latest GINA guidelines, i.e. respiratory symptoms and either bronchodilator reversibility (improvement in FEV1 of more than 12% of baseline (and at least 200 mL) after inhalation of 800 µg salbutamol). * Use of inhaled corticosteroids or either persistent symptoms of wheeze, cough, or dyspnea or regular use of β2 agonists at least once a week during the last 2 months. * PC20 methacholine \< 8 mg/ml. * Group 2. Non-asthmatic controls * No history of asthma. * No use of inhaled corticosteroids or β2-agonists for a period longer than 1 month. * No symptoms of wheeze, nocturnal dyspnea, or bronchial hyperresponsiveness. * PC20 methacholine \> 8 mg/ml, FEV1/FVC \> 70% and FEV1 \> 80% predicted.
Exclusion criteria
* FEV1 \<1.2 L, * Subjects must be able to adhere to the study visit schedule and other protocol requirements. * A subject is not eligible to enter and participate if he has not signed and dated a written informed consent form prior to participation in the study. * A subjects is not eligible to enter and participate if he does not agree that we inform his general practitioner. * Upper respiratory tract infection (e.g. colds), within 6 weeks. * Serious acute infections (such as hepatitis, pneumonia or pyelonephritis) in the previous 3 months. * Signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease. * Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence). * Known recent substance abuse (drug or alcohol). * Females of childbearing potential without an efficient contraception unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH \>40 mIU/mL or the use of one or more of the following acceptable methods of contraception: 1. Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy). 2. Hormonal contraception (implantable, patch, oral, injectable). 3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/cream/suppository. 4. Continuous abstinence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Single-cell transcriptomics bronchial epithelial cell (BEC) | december 2022 |
Countries
Netherlands
Contacts
Primary ContactMaarten van den Berge, Dr
Outcome results
None listed